



# GAIN THERAPEUTICS

Corporate Deck

May 2026

NASDAQ: GANX

# Forward-Looking Statements

Certain statements set forth in this presentation are forward-looking and reflect the Company's plans, beliefs, expectations and current views with respect to, among other things, future events and financial performance (collectively referred to herein as "forward-looking statements"). Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and are often characterized by the use of words such as "believe," "can," "could," "potential," "plan," "predict," "goals," "seek," "should," "may," "may have," "would," "estimate," "continue," "anticipate," "intend," "expect" or by discussions of strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause our actual results, performance or achievements or industry results to differ materially from historical results or any future results, performance or achievements expressed, suggested or implied by such forward-looking statements.

These include, but are not limited to, statements about the Company's ability to develop, obtain regulatory approval for and commercialize its product candidates; the timing of future IND submissions, initiation of preclinical studies and clinical trials, and timing of expected clinical results for our product candidates; the Company's success in early preclinical studies, which may not be indicative of results obtained in later studies or clinical trials; the outbreak of the novel strain of coronavirus disease, COVID-19, which could adversely impact our business, including our preclinical studies and any future clinical trials; the potential benefits of our product candidates; the Company's ability to obtain regulatory approval to commercialize our existing or any future product candidates; the Company's ability to identify patients with the diseases treated by our product candidates, and to enroll patients in clinical trials; the success of our efforts to expand our pipeline of product candidates and develop marketable products through the use of our Magellan platform; the Company's expectations regarding collaborations and other agreements with third parties and their potential benefits; the Company's ability to obtain, maintain and protect our intellectual property; the Company's reliance upon intellectual property licensed from third parties, including the license to use the Company's Magellan platform; the Company's ability to identify, recruit and retain key personnel; the Company's financial performance; developments or projections relating to the Company's competitors or industry; the impact of laws and regulations; the Company's expectations regarding the time during which it will be an emerging growth company under the JOBS Act; and other factors and assumptions described in the Company's public filings.

These statements are based on the Company's historical performance and on its current plans, estimates and projections in light of information currently available to the Company, and therefore, you should not place undue reliance on them. The inclusion of forward-looking information should not be regarded as a representation by the Company or any other person that the future plans, estimates or expectations contemplated by us will be achieved. Forward-looking statements made in this presentation speak only as of the date of this presentation, and the Company undertakes no obligation to update them in light of new information or future events, except as required by law.

You should carefully consider the above factors, as well as the factors discussed elsewhere in this presentation and our public filings, before deciding to invest in our common stock. The factors identified above should not be construed as an exhaustive list of factors that could affect the Company's future results and should be read in conjunction with the other cautionary statements that are included in this presentation and our public filings. New risks and uncertainties arise from time to time, and it is impossible for the Company to predict those events or how they may affect the Company. If any of these trends, risks or uncertainties actually occurs or continues, the Company's business, revenue and financial results could be harmed, the trading prices of its securities could decline, and you could lose all or part of your investment. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Trademarks, Service Marks, and Trade Names This presentation includes our trademarks, and trade names, which are protected under applicable intellectual property laws. This presentation also may contain trademarks, service marks, trade names, and copyrights of other companies, which are the property of their respective owners. Solely for convenience, the trademarks, service marks, trade names, and copyrights referred to in this presentation are listed without the TM, SM, ©, and ® symbols, but we will assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors, if any, to these trademarks, service marks, trade names, and copyrights.

Industry Information Market data and industry information used throughout this presentation are based on management's knowledge of the industry and the good faith estimates of management. We also relied, to the extent available, upon management's review of independent industry surveys and publications and other publicly available information prepared by a number of third-party sources. All of the market data and industry information used in this presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Although we believe that these sources are reliable, we cannot guarantee the accuracy or completeness of this information, and we have not independently verified this information. While we believe the estimated market position, market opportunity and market size information included in this presentation are generally reliable, such information, which is derived in part from management's estimates and beliefs, is inherently uncertain and imprecise. No representations or warranties are made by the Company or any of its affiliates as to the accuracy of any such statements or projections. Projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described above. These and other factors could cause results to differ materially from those expressed in our estimates and beliefs and in the estimates prepared by independent parties.

# Gain Therapeutics At – a - Glance



Established in 2017, IPO March 2021



Headquartered in Bethesda, MD with offices in Lugano, Switzerland, Barcelona, Spain



25 Employees



Founder and Executive Chairman:  
Dr. Khalid Islam



Partnered with several leading medical & scientific organizations

## Proprietary Platform enables novel therapeutic candidates

Our proprietary drug discovery platform, **Magellan™**, integrates AI-supported structural biology with proprietary algorithms and physics-based models to identify novel allosteric binding sites on disease-implicated proteins across all therapeutic areas.

The allosteric MOA enables us to generate the first-in-class / best-in-class product candidates in our developmental pipeline.

# GANX Investment Summary

## Clinical PoC for GT-02287; Disease-Modifying Treatment for Parkinson's Disease



- Completed **Phase 1a in healthy volunteers** and **Phase 1b open-label trial in PD** (90-day) with 84% of patients electing to join 9-month extension study
- Biomarker evidence from Phase 1b supports **disease-modifying potential** for GT-02287 in both GBA1 and idiopathic Parkinson's disease

## Multiple Near-Term Catalysts



- **Q2 2026** - FDA IND review clearance
- **Q3 2026** - Start of Phase 2 in people with Parkinson's disease
- **Q4 2026** – Final data from GT-02287 Phase 1b study

## Global Rights with Strong IP



- Full worldwide rights to GT-02287 with composition of matter **patent protection through 2038** (additional Hatch-Waxman extension for R&D)
- Patent applications for **5 NCE families** under review

## Strong Financial and Developmental Support from Scientific / Medical Community



Grant Support from:

- **Michael J. Fox Foundation** for Parkinson's research
- **The Silverstein Foundation** for Parkinson's with GBA research
- **Innosuisse** (Swiss Innovation Agency)

# Leadership: Extensive Biotech and Pharma Experience



**Gene Mack, MBA**  
Chief Executive Officer




**Jonas Hannestad, MD, PhD**  
Chief Medical Officer




**Joanne Taylor, PhD**  
SVP Research




**Khalid Islam**  
Chairman, Co-Founder




**Terenzio Ignoni, PharmD**  
SVP Technical Operations




**Gianluca Fuggetta**  
Senior Vice President, Finance



# Gain Therapeutics Pipeline

ASSET	INDICATION	TARGET	DISCOVERY	RESEARCH	PRECLINICAL	PHASE 1
GT-02287	Parkinson's Disease	GCase	Progress bar spanning Discovery, Research, and Preclinical stages.			
	Gaucher's Disease	GCase	Progress bar spanning Discovery and Research stages.			
	Dementia with Lewy Bodies	GCase	Progress bar spanning Discovery and Research stages.			
	Alzheimer's Disease	GCase	Progress bar spanning Discovery and Research stages.			
Multiple Undisclosed	Lysosomal Storage Disorders	GALC GLB1	Progress bar spanning Discovery and Research stages.			

# Parkinson's Disease: High Need for Disease-Modifying Therapies


Existing therapies address symptoms without slowing progression

## Parkinson's Disease

US Market Potential:

**\$4B**

- Second most common neurodegenerative disease after Alzheimer's
- People with PD inevitably get worse over time



## GBA1-PD

US Market Potential:

**\$3B**

- Most common genetically-defined subpopulation of PD
- GBA1 variants cause misfolding of glucocerebrosidase (GCase)
- Considerable overlap in pathobiology between GBA-PD and idiopathic PD
- A therapy targeting GCase-related pathway abnormalities is believed to slow disease progression in both GBA-PD and idiopathic PD

# GT-02287: A Disease-Modifying Therapy in Development for Parkinson's Disease

## Novel Mechanism

GT-02287 binds at allosteric site, and chaperones glucocerebrosidase (GCase) enzyme to lysosomes and mitochondria

## Disease Modification

Restores GCase function and improves disease cascade and neuronal survival in both GBA1 and iPD models

## Efficacy

Phase 1b shows statistically significant biomarker evidence of central target engagement with clinical improvement measured via MDS-UPDRS scores



## Safety/Tolerability

Well-tolerated in both healthy volunteers and PD patients with therapeutic CNS exposures achieved

## Next Steps


Start of Phase 2 trial in Q3 2026

# Dysfunctional GCase Affects Multiple Organelles




# Allosteric Modulator GT-02287 Restores GCase Function: Improves Disease Cascade to Promote Neuronal Survival (i.e., Disease-Modifying)

## Dopaminergic Neuron with Restored GCase Function




- Corrects protein misfolding
- Restores enzymatic activity


## GCase Activity Restoration




## Restored Lysosomal Function




## Toxic Substrate Depletion




## Reduced ER Stress




## Restored Mitochondrial Function



## Alpha-Synuclein Depletion




## Neuronal Survival




# GT-02287 Demonstrates a Disease-Modifying Effect in Animal Models of GBA1 and iPD

## GBA1- PD Model (CBE+PFFs)



## Idiopathic PD Model (PFFs only)



Mouse Wire Hang

- Control
- CBE/PFFs
- ◆ PFFs
- ▲ GT-02287 60mg/Kg
- ▼ GT-02287 90mg/Kg

# GT-02287 is Well-Tolerated in SAD/MAD and Bioavailability Studies

## Demonstrated CNS Exposure and GCase Engagement

### 79 Healthy Volunteers

- Single and multiple dose levels tested were **generally well-tolerated, with no SAEs** or Grade 3 (severe) adverse events observed; no other safety signals detected
- Most common treatment-related AEs (TEAEs) in MAD were nausea (32%), abdominal pain (8%), diarrhea (8%) and headache (8%)
- **Therapeutic exposure levels achieved** in line with results from preclinical models
- **CNS exposure** comparable to that observed in rodent studies

### GCase Activity in Dried Blood Spots (DBS)


GCase activity in dried blood spots was measured in MAD Cohort 4

5 out of 6 subjects had increased GCase activity. No increase was observed in PBO subjects

**53% increase in GCase activity observed by Day 14 ( $p < 0.001$ )\***

*\*One-way, paired, repeated measures ANOVA*


# Phase 1b Study Overview + 90 day and Open-Label Extension




## Overview:

- 3-month open label multi-center study across 7 sites (AU)
- 1x daily dose for 90 days
- **Objective:** Assess the Safety, Tolerability, PK/PD (blood & CSF) of GT-02287 in Parkinson's Disease patients with or without a pathogenic GBA1 mutation, along with mechanistic biomarkers, and clinical progression measured via MDS-UPDRS
- Phase 1 SAD/MAD First-in-human study demonstrated GCase target engagement in healthy volunteers


# Decreased GCCase Leads to Excess GluCer and Consequently Increased GluSph in Parkinson's



# GT-02287 Treatment Leads to a Decrease in CSF GluSph, a Prespecified Endpoint, Demonstrating CNS Target Engagement




Data are shown as mean  $\pm$  s.e.m.  $n=13$ .  $P < 0.05$  two-way ANOVA



Data are shown as CSF GluSph levels for individual patients before and after treatment. Gray lines represent patients with low CSF GluSph and green lines represent patients with high CSF GluSph at baseline

# Phase 1b Evaluable Population for CSF Biomarker Analysis and MDS-UPDRS Scores



# PD Patients With High Levels of CSF GluSph at Baseline Show a Markedly Greater Improvement in MDS-UPDRS Motor Scores After 90 Days of Treatment with GT-02287

Negative score indicates improvement of symptoms

All patients for which CSF GluSph and UPDRS scores available (n=14)

Part II	Part III	Part II+III
-0.6	-2.1	-2.7

Patients with **low** CSF GluSph (n=8)



Part II	Part III	Part II+III
0.1	-0.3	-0.2

Patients with **high** CSF GluSph (n=6)

Part II	Part III	Part II+III
-1.5	-4.7	-6.2*

Data shown as mean (n=14). Statistically significant difference as compared to low GluSph group. One-sample t-test. \*P < 0.05.

# Higher CSF DDC Levels in Participants Who Had High CSF GluSph at Baseline DDC Decreases Following GT-02287 Treatment in High GluSph Group



**DDC is elevated in CSF in people with Parkinson's, likely due to dopaminergic neuron dysfunction**

DOPA decarboxylase (DDC) is an enzyme responsible for converting *L*-DOPA (levodopa) into dopamine in the brain and peripheral nervous system.

*Data are mean  $\pm$  s.e.m. Analysed by unpaired t-test for difference between Low and High CSF GluSph groups.*

# GT-02287: A Disease-Modifying Therapeutic in Development for Parkinson's Disease

## Mechanism

GT-02287 binds at allosteric site, and chaperones glucocerebrosidase (GCase) enzyme to lysosomes and mitochondria

## Disease Modification

Restores GCase function and improves disease cascade and neuronal survival in both GBA1 and iPD models

## Efficacy

Phase 1b shows statistically significant biomarker evidence of central target engagement with clinical improvement measured via MDS-UPDRS scores

## Safety/Tolerability

Well-tolerated in both healthy volunteers and PD patients with therapeutic CNS exposures achieved

## Next Steps

Start of Phase 2 trial in Q3 2026


## GT-02287 Evidence:

- Patients with elevated baseline **CSF GluSph** had an average 81% reduction after 90 days of treatment
- Elevated baseline **DDC** in **high CSF GluSph** group also reduced following 90 days of treatment
- Clinically relevant improvement in **MDS-UPDRS Parts II + III** scores of 6.2 points in **high CSF GluSph** group

# Phase 2a Study

48-week, double blind, randomized, placebo-controlled Phase 2a study of 2 dose levels of oral GT-02287 in treated and untreated participants with early PD

Participants: Clinical diagnosis of PD according to Movement Disorder Society Criteria; time since diagnosis of no more than 5 years; positive SAA in CSF; Modified Hoehn and Yahr Stages 1 to 2.5; Idiopathic and GBA1, on stable dopaminergic treatment



# KOL Events and Industry Support

JANUARY 2026

## UNDERSTANDING GCASE SUBSTRATES IN PARKINSON'S DISEASE – PERSPECTIVES ON BIOMARKERS AND DISEASE MODIFICATION

Featured Key Opinion Leaders Roy Alcalay, M.D., M.Sc., Chief of Movement Disorders Division, Tel Aviv Sourasky Medical Center, Professor of Neurology, Tel Aviv University, Associate Professor of Clinical Neurology, Columbia University, and Peter Lansbury, Ph.D., Professor of Neurology, Harvard


 **REPLAY**

OCTOBER 2025

## BIOMARKERS, CLINICAL ENDPOINTS, AND THE PATH TO DISEASE MODIFICATION: CONTEXTUALIZING THE EMERGING DATE FROM GT-02287

Featured Key Opinion Leaders Karl Kieburtz, M.D., M.P.H., Professor of Neurology, University of Rochester and Kenneth Marek, M.D., President and Senior Scientist, Institute for Neurodegenerative Disorders

 **REPLAY**



# Financials



Established in 2017, IPO March 2021



Headquartered in Bethesda, MD with offices in Lugano, Switzerland, Barcelona, Spain



25 Employees



Founder and Executive Chairman:  
Dr. Khalid Islam



Partnered with several leading medical & scientific organizations

## Financials

- **Nasdaq: GANX**
- Cash: \$20.2 million as of December 31, 2025
- Cash Runway: through 1Q27
- No debt
- 42.1 million shares outstanding

# GANX Investment Summary

---

**Clinical PoC for GT-02287, a Disease-Modifying Treatment for Parkinson's Disease**

**Multiple Near-Term Catalysts**

**Global Rights with Strong IP**

**Strong Financial and Developmental Support from Scientific / Medical Community**

Thank you